Navigation Links
Webcast Alert: MicroRNA: The Year in Review
Date:12/9/2009

CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master regulator of the genome, and Dr. Stoffel will discuss the elucidation of microRNA function in normal and disease states, and therapeutic strategies based on microRNA modulation.


What:      MicroRNA: The Year in Review

When:      3 p.m. EST on Monday, December 14

Where:     http://www.videonewswire.com/event.asp?id=64631

How:       Live over the Internet -- Simply log on at the address above.


      Contact:

                      Regulus Therapeutics
                      Garry E. Menzel, Ph.D.
                      (760)268-6811

                      Media
                      Heidi Chokeir, Ph.D.
                      Russo Partners, LLC
                      (619)528-2217
                      heidi.chokeir@russopartnersllc.com

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from Alnylam Pharmaceuticals and Isis Pharmaceuticals (Alnylam and Isis jointly formed Regulus in 2007). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, cardiovascular disease and fibrosis, oncology, and immunology and inflammation. Regulus intellectual property estate contains both the fundamental and core patents in the field as well as over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. For more information, visit www.regulusrx.com.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com and at least a 56Kbps connection to the Internet.

If you experience problems listening to the webcast, send an E-mail to: webcast@multivu.com.

SOURCE Regulus Therapeutics Inc.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
2. Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications
3. Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today
4. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
5. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
6. Sunrise to Host Conference Call and Webcast to Discuss Third-Quarter 2009 Financial Results
7. Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday, November 4, at 10 A.M. EST
8. NHP Announces Third Quarter Earnings Release Date and Webcast/Conference Call
9. Smart Balance to Host Webcast/Conference Call on 2009 Third-Quarter Results
10. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results
11. CBIZ Webcasts Third-Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... in Central Michigan, has produced another video highlighting one of the many supplemental ... Arts class. Sensei Ed Taylor, a 5 th Degree Black Belt in the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Program (KOHP), a $500,000 two-year pilot initiative to improve oral health-related awareness, education, ... professional development for health care providers and promote best practices in 10 New ...
(Date:5/25/2016)... MA (PRWEB) , ... May 25, 2016 , ... ... Research Institute (WCRI) compare outcomes of injured workers across 15 states. The ... to work, earnings recovery, access to medical care, and satisfaction with medical care. ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of the ... ran one of Allstate’s most successful agencies for 48 years, but it was his ... award named for him is not given every year, but only when an agency ...
(Date:5/25/2016)... Puerto Vallarta, Mexico (PRWEB) , ... May 25, 2016 , ... ... menu surrounding the restorative properties of precious stones to complement its new wellness ... spread over two floors and feature a plethora of special services and insuite amenities, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... , May 24, 2016 Open ... in Clinical Neurophysiology  Elsevier , a ... and services, today announced the launch of ... access journal that focuses on clinical practice issues in ... reports, clinical series, normal values and didactic reviews. It ...
Breaking Medicine Technology: